Vivus Reveals Plans To Curb Costs As Qsymia Sales Lag
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s vague corporate update includes plans to focus the Qsymia sales team on the most productive areas and potential cost-saving measures for a planned cardiovascular outcomes trial.
You may also be interested in...
Qsymia Sales Reps Recruited For Experience With Metabolic Products
Vivus will benefit from downsizing at other firms, Chief Commercial Officer Mike Miller says. The company will aggressively seek formulary coverage, expects REMS to soothe payer concerns about appropriate use of the obesity product, he notes.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.